These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 31502084

  • 1. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.
    Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M.
    Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
    [Abstract] [Full Text] [Related]

  • 2. 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Prostate; 2018 Jan; 78(1):54-63. PubMed ID: 29105797
    [Abstract] [Full Text] [Related]

  • 3. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.
    Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, Bäuerle T, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Clin Nucl Med; 2018 Apr; 43(4):225-231. PubMed ID: 29401151
    [Abstract] [Full Text] [Related]

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Apr; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 5. 99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
    Schmidkonz C, Götz TI, Atzinger A, Ritt P, Prante O, Kuwert T, Bäuerle T, Goebell P, Cordes M.
    Clin Nucl Med; 2020 Aug; 45(8):e349-e357. PubMed ID: 32558706
    [Abstract] [Full Text] [Related]

  • 6. 99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions.
    Schmidkonz C, Atzinger A, Goetz TI, Beck M, Ritt P, Prante O, Kuwert T, Bäuerle T, Cordes M.
    Clin Nucl Med; 2020 Feb; 45(2):105-112. PubMed ID: 31876822
    [Abstract] [Full Text] [Related]

  • 7. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C, Zhu Y, Su H, Xu X, Zhang Y, Ye D, Hu S.
    Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
    [Abstract] [Full Text] [Related]

  • 8. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.
    Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.
    J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 10. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax.
    Yilmaz U, Komek H, Can C, Altindag S.
    Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
    [Abstract] [Full Text] [Related]

  • 11. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
    Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
    [Abstract] [Full Text] [Related]

  • 12. Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study.
    Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, Czernin J, Calais J, Pávics L.
    J Nucl Med; 2021 Aug 01; 62(8):1075-1081. PubMed ID: 33277398
    [Abstract] [Full Text] [Related]

  • 13. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
    Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M.
    Clin Nucl Med; 2016 Sep 01; 41(9):e397-402. PubMed ID: 27276206
    [Abstract] [Full Text] [Related]

  • 14. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
    Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ.
    J Nucl Med; 2014 Nov 01; 55(11):1791-8. PubMed ID: 25342385
    [Abstract] [Full Text] [Related]

  • 15. First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer.
    Reinfelder J, Kuwert T, Beck M, Sanders JC, Ritt P, Schmidkonz C, Hennig P, Prante O, Uder M, Wullich B, Goebell P.
    Clin Nucl Med; 2017 Jan 01; 42(1):26-33. PubMed ID: 27775936
    [Abstract] [Full Text] [Related]

  • 16. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
    Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.
    Ann Surg Oncol; 2019 Feb 01; 26(2):653-659. PubMed ID: 30324468
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
    Su HC, Zhu Y, Ling GW, Hu SL, Xu XP, Dai B, Ye DW.
    Asian J Androl; 2017 Feb 01; 19(3):267-271. PubMed ID: 27976632
    [Abstract] [Full Text] [Related]

  • 18. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, Darendeliler E, Ozluk Y, Yildiz SO, Turkmen C.
    Ann Nucl Med; 2017 Nov 01; 31(9):709-717. PubMed ID: 28900854
    [Abstract] [Full Text] [Related]

  • 19. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.
    J Nucl Med; 2013 Aug 01; 54(8):1369-76. PubMed ID: 23733925
    [Abstract] [Full Text] [Related]

  • 20. [99mTc]Tc-HYNIC-ALUG SPECT/CT in the initial staging of 227 consecutive patients with newly diagnosed prostate cancer: a 5-year monocentric retrospective study.
    Li B, Ding X, Duan L, Shi J, Tang M, Zhang J, Zhao Z, Wu X, Gao Y.
    Front Endocrinol (Lausanne); 2024 Aug 01; 15():1326858. PubMed ID: 38449842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.